The chief medical officer at Clene Nanomedicine discussed the recently presented data on CNM-Au8 from the VISIONARY-MS trial.
Robert Glanzman, MD
Advertisement
Articles by Robert Glanzman, MD
The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.
Advertisement
Latest Updated Articles
Robert Glanzman, MD: Overview of CNM-Au8Published: March 17th 2020 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
2
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
3
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
4
Decision-Making in De-Escalating Therapy for Multiple Sclerosis
5
